- This topic is empty.
I found this company in the Health Care field, specifically related to gene-editing and gene-related diseases, which deals with the transporting of gene-editing technologies into the cell more safely, effectively and affordably than anything existing today in the market (as they stated in the website). They also claim that they could reduce the costs of cutting-edge cancer fighting therapies like CAR-T by up to 50%.
The company was founded by a former Dow Chemical VP who has a good track record in increasing profits for the company.
Neil and team: Do you have this company in your sights? Can this be a company worth of being added to our site?
I actually see this company as a candidate (it checks several of the important points for a possible winner), but would like your input on it. You can check it in the Equifund CFP website, or directly by searching it in the web.
- You must be logged in to reply to this topic.